

# EPI Country Report

## GRENADA, 2019



### Demographics and socioeconomic

Total Population (in 1000) (2019)	112.00
Population <1 year of age (in 1000) (2019)	1.77
Population 1 year of age (in 1000)(2019)	1.80
Population <5 years of age (in 1000) (2019)	9.06
Women of childbearing age (2019)	56.81
Infant Mortality Rate (per 1000 live births) (2018)	12.50
Gross national income (US\$ per capita) current value (2018)	9,780.00
National Health Expenditure Public (2016)	2.17
National Health Expenditure Private (2016)	3.03

### Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 3.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 3 times in 2019.
- 100% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry is in place.


### Immunization Schedule

GRD	Doses					
	1	2	3	4	5	6
BCG						
HepB_Pediatric	At Birth					
DTP-Hib						
DTP-Hib-HepB	W6-8	M4	M6			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV				M18		
DTP						
IPV	W6-8					
OPV		M 4	M6	M18	Y4-5	Y14-15
MMR	M12	M18				
Pneumoco_conj						
Rotavirus						
Td					Y14-15	
TdaP						
HPV	9YRS	10YRS				

### Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	2000
Hepatitis B	2000
HPV	
Influenza	2006
MMR1	1993
MMR2	2000
Pentavalent	2000
Pneumococcal Conjugate	
Rotavirus	
Tdap	
Tetraivalent DPT-Hib or DPT-HepB	
Yellow Fever	

### Vaccination Coverage



### Surveillance Indicators - AFP (CARPHA)


	2019
Number od AFP suspected cases	8
AFP rate per 100,000 population <15 years old	0.57
% of cases with 1 adequate samples	100
% of cases investigated within <48 hours	100
% sites reporting	83

### Surveillance Indicators - MR (CARPHA)


	2019
Number of suspected cases	371
% of cases with adequate investigation	86
% of cases with adequate blood samples	98
% of samples received in laboratory <=5 days	9
% of laboratory samples results <=4 days	83




### Polio3 coverage and AFP rate per 100,000 children <15 years of age




### DTP3 coverage and number of reported diphtheria and pertussis cases




### Number of tetanus (no neonatal) and neonatal tetanus cases



### Proportion of municipalities by coverage range with DTP3 in children <1 years of age



### DTP1-DTP3 and DTP1-MMR1 Dropout Rate



**Legend**  
 NB/nb-newborn  
 M/m-month  
 Y/y-year  
 WCBA-women of childbearing age

- with stockout
- no stockout
- no data available

### Vaccine Stockout

